论文部分内容阅读
为研制治疗流行性出血热的有效药物,用出血热疫苗加佐剂免疫羊,取其肝、脾、淋巴结,用热酚法提取iRNA,制成冻干注射剂,进行临床观察。将流行性出血热患者48例分综合治疗组、病毒唑组和治疗组3组。一般疗法相同,后两组分别加用病毒唑或出血热免疫核糖核酸(EHF-iRNA)。结果显示:治疗组病人血小板、尿蛋白、体温复常时间明显缩短(P<0.05),症状减轻,越期率增加。提示EHF-iRNA经临床初步应用已显示有一定的疗效,未发现任何副作用,值得进一步研究开发。
In order to develop an effective drug for the treatment of epidemic hemorrhagic fever, the sheep were immunized with the hemorrhagic fever vaccine and adjuvant, the liver, spleen and lymph nodes were taken from the liver, and the iRNA was extracted by hot phenolic method to make lyophilized injection for clinical observation. 48 patients with epidemic hemorrhagic fever were divided into comprehensive treatment group, ribavirin group and treatment group 3 groups. The same general treatment, the latter two groups were added ribavirin or hemorrhagic fever with immune RNA (EHF-iRNA). The results showed that the platelet and urine protein in the treatment group were significantly shorter than those in the control group (P <0.05), and the symptoms were relieved and the overdue rate increased. Prompt EHF-iRNA preliminary clinical application has shown some efficacy, did not find any side effects, it is worth further research and development.